Lowering costs won’t improve health outcomes if the pharmacies dispensing those medications lack the authority, staffing, and infrastructure to function as clinical settings.
When policy makers discuss prescription drugs, they almost always talk about price. From Trump-era “Rx” proposals to bipartisan insulin caps championed by leaders like US Sen Raphael Warnock (D, Georgia), the dominant assumption is clear: If medications are cheaper, Americans will be healthier. It is a noble goal, and in many cases, a necessary one. But it is also incomplete. Affordability does not guarantee access when the system responsible for dispensing those drugs lacks the capacity, authority, and infrastructure to function as the clinical setting it already is.
As a certified pharmacy technician for one of the largest retail pharmacies in the country, I’ve learned that community pharmacies are among the largest and most frequently used points of care in the United States. They are not merely retail spaces where prescriptions are scanned and stapled. They are where millions of Americans receive the most consistent, informal, and often urgent health care of their lives. Yet our policy framework continues to treat these encounters as transactions rather than clinical care, and patients pay the price for that mismatch.
Consider the man whose blood thinner suddenly cost nearly $500. He stared at the register, silently calculating which bill could be delayed this month. It took over an hour of calls to his insurer, searching for co-pay assistance and navigating coverage loopholes, before the cost dropped to $50. The relief he felt was not about saving money; it was about avoiding a stroke. That intervention prevented a medical emergency, yet under current policy, none of that labor counts as care.
Or the panicked caller convinced he had poisoned himself after accidentally swallowing the small silica packet in his medication bottle. Hospitals are built for heart attacks and sepsis, not for everyday medical confusion. Pharmacies, however, catch all of it. They function as an informal triage system for concerns too small and too expensive for urgent care but too frightening to ignore. When people don’t know whom to ask, they ask the pharmacy.
Then there was the patient who shattered their only vial of insulin on the kitchen floor. They were out of refills and weeks away from their next appointment, a situation that could easily escalate into a medical crisis. Many states allow certain types of insulin to be purchased without a prescription, but the patient didn’t know that. Even with insulin price caps in place, cost protections mean little if patients can’t navigate access in real time. This wasn’t a failure of pricing policy; it was a failure of capacity.
Stories like these are not exceptions. They are the daily, unglamorous backbone of American health care. Pharmacies have become de facto clinical hubs not by design, but by necessity, because other parts of the health care system are too expensive, too scarce, too rushed, or too difficult to navigate. Yet policy has not caught up to this reality. We have assigned pharmacies clinical responsibility without granting them clinical recognition.
According to the CDC, more than 60% of American adults take at least 1 prescription medication each year.¹ That means most people interact with a pharmacy far more often than they see a physician or enter a hospital. But unlike exam rooms or inpatient units, pharmacies are given little structural support to absorb the clinical needs that inevitably surface at their counters. What I witness behind that counter—the financial emergencies, medical confusion, and quiet crises that never make it into charts—reveals a gap that policy makers rarely acknowledge.
Recent drug pricing reforms represent meaningful progress. They save lives. But they also expose a deeper oversight: policy makers are addressing what drugs cost without addressing whether the system that dispenses them can function sustainably. Lower prices increase demand and reliance on pharmacies, but staffing levels, reimbursement structures, and scope-of-practice laws remain largely unchanged. The result is a system that asks pharmacies to do more with no additional support.
Now, as a nursing student, I spend my time in exam rooms and inpatient units, the spaces most often recognized as “real” clinical settings. But I cannot unsee what I learned in the pharmacy. Most health care does not occur during hospital admissions or scheduled appointments. It happens in 30-second conversations at the counter, in moments of financial panic, in misread labels and misunderstood instructions, and in the daily management of chronic illness.
Nursing will teach me how to care for patients at their sickest; pharmacy work taught me how often patients are placed at risk by the system itself.
For lawmakers serious about improving access to care, this distinction matters. Focusing on drug prices without investing in pharmacy infrastructure is like subsidizing airline tickets while neglecting the airports. If community pharmacies are where patients show up first, often before they even realize they are seeking care, then policy must reflect that reality.
That means clearer clinical authority for pharmacists, such as nationwide provider status that allows them to bill Medicare and private insurers for medication therapy management, chronic disease monitoring, contraceptive prescribing, smoking cessation treatment, and point-of-care testing. It means reimbursing pharmacies for the clinical labor already happening at the counter: the hour spent securing an affordable anticoagulant, the emergency insulin bridge, and the intervention that prevents a dangerous drug interaction. It means reimbursement models that pay for outcomes and counseling time, not just the act of dispensing a bottle.
Caroline Rubin is a Bachelor of Science in Nursing student in the Honors Program at the Nell Hodgson Woodruff School of Nursing at Emory University. She works as a certified pharmacy technician for one of the nation’s largest retail pharmacy chains, where she has witnessed firsthand the gaps between drug pricing policy and real-world access. Her interests include health care infrastructure, pharmacy reform, and patient-centered policy.
It also means staffing models tied to prescription volume and patient complexity, not retail sales metrics, so pharmacists are not forced to choose between safety and speed. And it requires public health strategies that formally integrate pharmacies into emergency preparedness planning, from vaccine distribution to antiviral access, recognizing what became undeniable during COVID-19: community pharmacies are not optional conveniences; they are health care infrastructure. Until then, we will continue mistaking cost control for care.
Working behind the pharmacy counter did more than teach me how to fill prescriptions. It showed me what patients look like when the health care system fails them and how often a pharmacy prevents that failure from becoming a crisis. Community pharmacies are not the back office of health care; they are its front porch. As I move forward in the field, I carry that lesson with me: Care does not begin at admission and does not end at discharge. It begins where people show up first, at the pharmacy counter, long before anyone reaches the front door.
